Moderna has slowed down enrollment for its late-stage coronavirus vaccine trials. This is due to its private contractors not enlisting enough minority participants yet. By mid-September, only 7% of trial enrollees were Black Americans, yet their participation should more closely reflect the 13% of the U.S. population which is Black. (Reuters)
Amgen’s cancer tumor treatment had a “positive” effect on tumor shrinkage. These findings were related to a Phase 2 clinical trial with patients with advanced lung cancer. Yet the lack of detail in the report to support those conclusions is unusual and could be a cause for concern about efficacy and the prospects for FDA approval. (STAT)
Multisystem inflammatory syndrome in children, a coronavirus-associated disorder that causes general inflammation, has been found in adults, according to CDC researchers. Multisystem inflammatory syndrome in adults disproportionately affects racial and ethnic minorities. (WebMD)
Vir Biotechnology is expanding its Phase 3 clinical trial for VIR-7831, a monoclinal antibody treatment for COVID-19 patients facing a high risk of hospitalization. The randomized study will evaluate 1,300 non-hospitalized patients who tested positive for the coronavirus. (MarketWatch)
Interested in a discussion on end-to-end labeling management? Join MM+M and Amplexor for a webcast on the topic today at 1 p.m. ET. (MM+M)
